Medicxi pioneers ‘exit and reinvest’ for biotech sector with €200m close of debut secondaries fund

European life sciences investor Medicxi has hit a €200m final close for its debut secondaries fund amid using the vehicle to pick up six companies from one of the firm's previous funds.